Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Magnetic resonance spectroscopic imaging for prostate disease detection: clinical and cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2014 Authors' conclusions One health technology assessment, two systematic reviews, one randomized controlled trial, five non-randomized studies, and two evidence-based guidelines were identified regarding magnetic resonance spectroscopic imaging compared with ultrasound-guided transrectal biopsy for prostate disease diagnosis. Indexing Status Subject indexing assigned by CRD MeSH Magnetic Resonance Spectroscopys; Prostate Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000822 Date abstract record published 16/07/2014 |